Výsledky vyhledávání - "Michele Bourke"

358 Trial in progress: A pilot study of combined immune checkpoint inhibition in combination with ablative therapies in subjects with hepatocellular carcinoma (HCC)

Autor: Stephen Stewart, Hailey Kathryn Carroll, Peter Doran, Ronan Ryan, Tim F. Greten, Cliona O'Farrelly, Austin G. Duffy, Marie Galligan, Umair Aleem, Michele Bourke, Diarmaid D. Houlihan, Pooja Varghese, Katherine Hoey, Raymond S. McDermott

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)

Background Locoregional therapies for hepatocellular carcinoma, such as transcatheter arterial chemoembolization (TACE) or ablation, can induce a peripheral anti-tumor immune response. This may be amplified by immune checkpoint inhibitors (ICI). Earl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edcffdab09ffff539e762b5a0607fb3c
https://doi.org/10.1136/jitc-2020-sitc2020.0358

Zobrazit plný text záznamu

Tremelimumab (day 1 only) and durvalumab in combination with transarterial chemoemobilization (TACE) in patients with hepatocellular carcinoma (HCC)

Autor: Jemma Buchalter, Niamh Evans, Iseult Browne, Colm Mac Eochagain, Calvin Flynn, Hailey Kathryn Carroll, Marie Galligan, Michele Bourke, Amy Lester-Grant, Katherine Hoey, Ronan Ryan, Colin P Cantwell, Jeffrey McCann, Ray McDermott, Ross MacNicholas, Austin G Duffy

Publikováno v: Journal of Clinical Oncology. 40:451-451

e16175 Background: TACE induces a peripheral anti-tumor immune response, which may be amplified by immune checkpoint inhibitors (ICI). Combining TACE with dual ICI therapy has been shown to be safe and feasible. Recent data has suggested that Day-1 o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8053962540f7211c3ffd2b06b6d40598
https://doi.org/10.1200/jco.2022.40.4_suppl.451

Zobrazit plný text záznamu

Trial-in-progress: A pilot study of combined immune checkpoint inhibition in combination with ablative therapies in subjects with hepatocellular carcinoma (HCC)

Autor: Pooja Varghese, Umair Aleem, Stephen Stewart, Peter Doran, Cliona O'Farrelly, Raymond S. McDermott, Michele Bourke, Ronan Ryan, Hailey Kathryn Carroll, Diarmaid D. Houlihan, Marie Galligan, Katherine Hoey, Tim F. Greten, Austin G. Duffy

Publikováno v: Journal of Clinical Oncology. 39:TPS355-TPS355

TPS355 Background: Locoregional therapies for hepatocellular carcinoma, such as transcatheter arterial chemoembolization (TACE) or ablation, can induce a peripheral anti-tumor immune response. This may be amplified by immune checkpoint inhibitors (IC

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b0108f9c6958b5da2f6f953c9dbb4c99
https://doi.org/10.1200/jco.2021.39.3_suppl.tps355

Zobrazit plný text záznamu